Madrigal to Present Multiple Abstracts at AASLD's The Liver Meeting 2026, Including New Real-World Evidence Reinforcing Rezdiffra as a Foundational Therapy for MASH

What happened

Madrigal Pharmaceuticals announced that thirteen abstracts on Rezdiffra will be presented at AASLD's The Liver Meeting, held Nov. 5-9 in Denver. The abstracts come from its RESONANCE real-world evidence program and examine treatment patterns, monitoring, adherence and persistence among thousands of patients.

Confirmed

Global impact / market context

Real-world data showing how Rezdiffra performs outside clinical trials can support the drug's role as a foundational MASH therapy, which means doctors may prescribe it more broadly. Stronger physician adoption could lift Madrigal's product revenue and justify continued spending on evidence generation.

Analyst inference

For investors, the presentations offer a near-term catalyst that could shape expectations for Rezdiffra's commercial trajectory. Evidence of adherence and persistence matters because patients staying on therapy longer supports recurring revenue, while poor persistence would raise questions about the size of the addressable market.

Analyst inference

What to watch

1. Madrigal will present thirteen abstracts from its RESONANCE program at AASLD's The Liver Meeting in Denver, covering real-world treatment patterns, monitoring, adherence and persistence among thousands of Rezdiffra patients. Confirmed
2. Investors should watch whether the presented data show adherence and persistence levels that support durable revenue, which means patients continuing treatment over time rather than stopping early. Proposed
3. Any evidence of improving patient outcomes in routine practice could strengthen Rezdiffra's position as a foundational therapy, which may influence how doctors adopt it and how investors value Madrigal's growth outlook. Analyst inference

Evidence

• globenewswire.com